Reformulated OxyContin® (oxycodone HCl controlled-release or ORF) was developed as a tamper and abuse-deterrent product, to reduce the risk of product abuse, misuse and their consequences. This noninterventional single-session study asked participants who were medically-healthy recreational opioid users, aged 18 years and older, to consider how they would use commonly available supplies to tamper with placebo ORF and placebo original OxyContin (OC) tablets, and how they would assess the attractiveness of tampering and abusing ORF tablets, as compared with other opioid formulations. Participants provided information on past opioid use, and they assessed the properties of five nonhypothetical oxycodone products and two hypothetical oxycodone products. Participants provided feedback on tampering preferences, preferred tamper methods for each product, overall tampering potential and product preferences. We had 30 participants (27 males and 3 females; mean age 35 years, range 18–51) complete both the interview and tampering sessions. Participants judged OC as the most attractive, valuable, desirable and most likely to be tampered with, from among all opioid products studied. By contrast, they rated ORF as the least attractive, least valuable, least desirable, and least likely to be tampered with among all the nonhypothetical opioid products studied. These results suggested that recreational drug abusers view ORF tablets as tamper-deterrent products.
BudmanSHGrimes SerranoJMButlerSF (2009) Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduct J6: 8.
4.
ButlerSFBlackRACassidyTA. (2011) Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J8: 29.
5.
ButlerSFCassidyTAChilcoatH. (2013) Abuse rates and routes of administration of reformulated extended-release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain14(4): 351–358.
6.
ButlerSFFernandezKCChangA. (2010) Measuring attractiveness for abuse of prescription opioids. Pain Med11: 67–80.
7.
CariseDDugoshKLMcLellanAT. (2007) Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry164: 1750–1756.
8.
Centers for Disease Control and Prevention (2010) Emergency department visits involving nonmedical use of selected prescription drugs–United States, 2004–2008. Morb Mortal Wkly Rep59: 705–709.
9.
CiceroTJInciardiJAMuñozA (2005) Trends in abuse of OxyContin® and other opioid analgesics in the United States: 2002–2004. J Pain6: 662–672.
10.
ColucciSHarrisSPerrinoPJ. (2012) Safety, tolerability, and pharmacokinetics of crushed intranasal oxycodone tamper-resistant tablets and OxyContin® in healthy adults. Available at: www.cpdd.vcu.edu/Pages/Meetings/CPDD12AbstractBook.pdf (accessed 12 November 2012).
11.
CoplanPMChilcoatHDBaumgartnerT. (2012) Design of a post-marketing study program to assess the effects of a reformulated extended-release oxycodone tablet on its abuse. Pharmacoepidemiol Drug Safety21: 446.
InciardiJASurrattHLKurtzSP. (2007) Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med8: 171–183.
19.
JohansonC-EBalsterRLHenningfieldJE. (2009) Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: Expert panel report. Drug Alcohol Depend105: S65–71.
20.
KatzNDartRCBaileyE. (2011) Tampering with prescription opioids: Nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse37: 205–217.
21.
KatzNFernandezKChangA. (2008) Internet-based survey of nonmedical prescription opioid use in the United States. Clin J Pain24: 528–535.
22.
KatzNPAdamsEHChilcoatH. (2007) Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain23: 648–660.
23.
McCollSSellersEM (2006) Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend83: S52–62.
24.
OkieS (2010) A flood of opioids, a rising tide of deaths. N Engl J Med363: 1981–1985.
RaffaRBPergolizziJVJr (2010) Opioid formulations designed to resist/deter abuse. Drugs70: 1657–1675.
27.
SchneiderJPMatthewsMJamisonRN (2010). Abuse-deterrent and tamper-resistant opioid formulations: What is their role in addressing prescription opioid abuse?CNS Drugs24: 805–810.
28.
SellersEMSchullerRRomachMK. (2006) Relative abuse potential of opioid formulations in Canada: A structured field study. J Opioid Manag2: 219–227.
29.
SmithHS (2011) Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing. Expert Opin Pharmacother12: 1111–1125.
30.
StrangJBearnJFarrellM. (1998) Route of drug use and its implications for drug effect, risk of dependence and health consequences. Drug Alcohol Rev17: 197–211.
31.
Substance Abuse and Mental Health Services Administration (2005) Nonmedical oxycodone users: A comparison with heroin users. Available at: www.samhsa.gov/data/2k5/oxycodoneH/oxycodoneH.htm. (accessed 6 June 2012).
32.
Substance Abuse and Mental Health Services Administration (2007) Patterns and trends in nonmedical prescription pain reliever use: 2002 to 2005. Available at: www.oas.samhsa.gov/2k7/pain/pain.pdf. (accessed 6 June 2012).
VosburgSKJonesJDManubayJM. (2012) Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend126 (1–2): 206–15.
35.
WarnerMChenLHMakucDM (2009) Increase in fatal poisonings involving opioid analgesics in the United States, 1999–2006. NCHS Data Brief : 1–8.
36.
WebsterLR (2011) Oxycodone extended-release using gel-cap technology to resist alteration and abuse for the treatment of moderate-to-severe pain. Pain Manage1: 417–425.
37.
WebsterLRBathBMedveRA (2009) Opioid formulations in development designed to curtail abuse: Who is the target?Expert Opin Investig Drugs18: 255–263.
38.
WebsterLRJohnsonFKStaufferJ. (2011) Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs R D11: 259–275.
39.
YoungAMHavensJRLeukefeldCG (2010) Route of administration for illicit prescription opioids: A comparison of rural and urban drug users. Harm Reduct J7: 24.
